CLINICAL_TRIALS
withdrawal
· 2012-06-11
Clinical Trial Update: Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma [Phase 3]
Summary
A Phase 3 trial comparing Transarterial Chemoembolization (TACE) versus CyberKnife for recurrent hepatocellular carcinoma has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Albert Koong | Conditions: Carcinoma, Hepatocellular | Phase 3 | Status: WITHDRAWN